

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 826 673 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:
04.03.1998 Bulletin 1998/10

(51) Int. Cl.⁶: C07D 239/34, C07D 239/42,
A61K 31/505

(21) Application number: 96909327.7

(86) International application number:
PCT/JP96/00977

(22) Date of filing: 10.04.1996

(87) International publication number:
WO 96/32383 (17.10.1996 Gazette 1996/46)

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE
Designated Extension States:
AL LT LV SI

- HINO, Katsuhiko
Nara 636 (JP)
- FURUKAWA, Kiyoshi
Shiga 520-05 (JP)
- OKA, Makoto
Osaka 567 (JP)
- ITOH, Mari
Osaka 565 (JP)

(30) Priority: 13.04.1995 JP 113937/95


(71) Applicant:
DAINIPPON PHARMACEUTICAL CO., LTD.
Osaka-shi, Osaka 541 (JP)

(74) Representative:
Coleiro, Raymond et al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)

(72) Inventors:
• MURATA, Teruya
Osaka 595 (JP)

(54) ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME

(57) Acetamide derivatives represented by general formula (I) and physiologically acceptable acid-addition salts thereof, wherein X represents -O- or -NR₄; R₁ represents H, lower alkyl, lower alkenyl or cycloalkyl(lower)alkyl; R₂ represents lower alkyl, cycloalkyl, optionally substituted phenyl, etc.; R₃ represents H, lower alkyl or hydroxy(lower)alkyl; R₄ represents H, lower alkyl, etc.; R₅ represents H, lower alkyl, lower alkenyl, hydroxy(lower)alkyl, etc.; R₆ represents H, lower alkyl, CF₃ or optionally substituted phenyl, or R₅ and R₆ together form -(CH₂)_n; R₇ represents H, halogeno, lower alkyl, lower alkoxy, CF₃, OH, NH₂, etc.; and R₈ represents H, halogeno, lower alkyl or lower alkoxy. The compounds act selectively on the peripheral BZ_{ω3} receptor and exhibit excellent pharmacological effects, which makes them useful as a remedy and preventive for central diseases, for example, diseases associated with anxiety, depression and epilepsy, etc.



(I)

EP 0 826 673 A1